Skip to content
Menu

Freenome, Inc. FRNM

Full chart Compare
Set alert

Price alert · FRNM

All alert types
9.93 USD +0.20 (+2.00%)

Regular-session close

9.90 -0.03 -0.25%

After hours · Nov 19, 5:45 PM ET

9.85 Day range 10.51
9.73 52-week range 17.11
YTD
-23.83%
1 year
-7.67%

5D -1.27 (-11.55%)

1010.5011ThuFriMonTueWed9.73
Market cap
1.11B
Revenue (ttm)
217.86M
Profit margin
-50.83%
EPS (ttm)
-1.30
Shares out
111.50M
Forward P/E
-3.97
YTD return
-23.83%
1-year return
-7.67%
50-day average
13.60
200-day average
12.31
Volume
875.40K
Avg volume
835.42K
Open
9.85
Previous close
9.73
Day's range
9.85 – 10.51
52-week range
9.73 – 17.11
Beta
0.60
Analysts
Strong Buy
Price target
18.00 (+81.4%)
Earnings date
Dec 2, 2026

Key statistics

Enterprise value
850.46M
Price / sales
5.08
Price / book
2.29
Revenue growth
17628.40%
Total cash
429.97M
Total debt
201.66M
Return on equity
-35.90%

Fundamental scorecard

7 of 25 checks passed on FRNM’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 0 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
FRNM Revenue — quarterly 183.49M
FRNM Net income — quarterly 60.11M
FRNM EPS — quarterly 0.60

Earnings

FRNM recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 2, 2026Dec 30, 20260.1375———
Nov 10, 2026Sep 30, 20260.13751.10+0.96+700.00%
Jul 15, 2026Jun 30, 2026-1.78-1.91-0.13-7.61%

Upgrades / downgrades

FRNM analyst upgrades and downgrades
DateFirmActionFromTo
Aug 20, 2026Guggenheiminit—Buy
Aug 18, 2026TD Coweninit—Buy
Aug 17, 2026Jefferiesinit—Buy
Aug 17, 2026BTIGinit—Buy

About Freenome, Inc.

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen™ CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
freenome.com

News

Your note

Sign in to keep a note on FRNM — it syncs with the Stock Master app.

Insider holders

FRNM insider holders
InsiderRelationLatest transactionDateShares held
ALTMAN MICHAEL SETHFormerConversion of Exercise of derivative securityJul 19, 20260
EDELMAN JOSEPH EBeneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Jul 19, 20260
MCKENNA MARK CFormerConversion of Exercise of derivative securityJul 19, 202630,000
PERCEPTIVE CAPITAL SOLUTIONS HOLDINGSBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityJul 19, 20260
RA CAPITAL MANAGEMENT, L.P.Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Jul 19, 20260
SONG KENNETH M.D.FormerConversion of Exercise of derivative securityJul 19, 202630,000

Institution ownership

FRNM institution ownership
Holder% heldSharesValueReported
RA Capital Management, L.P.13.78%15,367,270152.52MSep 29, 2026
Perceptive Advisors Llc11.31%12,606,053125.12MSep 29, 2026
a16z Capital Management, L.L.C.5.00%5,571,59955.30MSep 29, 2026
Farallon Capital Management LLC3.35%3,733,75737.06MSep 29, 2026
Price (T.Rowe) Associates Inc2.74%3,055,03830.32MSep 29, 2026
ARK Investment Management, LLC2.50%2,787,70727.67MSep 29, 2026

Fund ownership

FRNM fund ownership
Holder% heldSharesValueReported
ARK Venture Fund1.81%2,019,29120.04MJul 30, 2026
ARK ETF Trust-ARK Genomic Revolution ETF1.59%1,773,07317.60MOct 30, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund0.36%397,3403.94MSep 29, 2026
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund0.22%241,4992.40MSep 29, 2026
T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Global Stock Fd.0.21%238,8552.37MJul 30, 2026
Federated Hermes World Investment Series, Inc.-Federated Hermes Intl S0.12%137,0001.36MSep 29, 2026